In the current study, 44 patients were tested for tumor gene mutations, and multiple statistical analysis methods (lasso regression + logistic regression + machine learning random forest algorithm) were used to find that patients with KRAS mutations benefited from PD‐1 blockade. The gene discussed is PDCD1; the disease is neoplasm.